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In this contribution we investigated whether Surface-Enhanced Raman Scattering (SERS) of 
serum can be a candidate method for detecting “luminal A” breast cancer (BC) at different stages. We 
selected three groups of participants aged over 50 years: 20 healthy women, 20 women with early 
localized small BC and 20 women affected by BC with lymph node involvement. SERS revealed clear 
spectral differences between these three groups. A predictive model using Principal Component 
Analysis (PCA) and Linear Discriminant Analysis (LDA) was developed based on spectral data, and its 
performance was estimated with cross-validation. PCA-LDA of SERS spectra could distinguish healthy 
from BC subjects (sensitivity: 92%; specificity: 85%), as well as subjects with BC at different stages, 
with a promising diagnostic performance (sensitivity and specificity ≥ 80%; overall accuracy: 84%). 
Our data suggest that SERS spectroscopy of serum, combined with multivariate data analysis, 
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represents a minimally invasive, easy to use and fast approach to discriminate healthy from BC 
subjects, and even to distinguish BC at different clinical stages. 
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INTRODUCTION 
Breast cancer (BC) is the most common cause of cancer death in women worldwide [1], as well 
as the most common noncutaneous cancer in European women [2, 3]. In Europe, BC is more frequently 
diagnosed in women aged over 50 years, with 49% of cases in the age range 50-69 and 31% of cases in 
the range 70-99 [4]. At diagnosis, early-stage tumors are more frequent than advanced-stage ones: 
tumors confined to breast (N0M0) represent 49.9% of diagnosed BC, while 32.8% of cases are locally 
advanced tumors, i.e. tumors spread to regional lymph nodes (N+M0) [4]. Metastatic tumors spread to 
distant organs (M1) are rarer, counting only for 5% of cases [4]. 
BC is a molecularly heterogeneous disease; indeed, gene expression profiling of BC has 
identified two biologically distinct estrogen receptor (ER)-positive subtypes of BC: luminal A and 
luminal B. Luminal A subtype is defined as being ER positive, HER2 (Human Epidermal grow factor 
Receptor 2) negative, and Ki67 low (≤ 14% cells positive), whereas luminal B subtype is ER positive, 
often negative, and Ki67 high (≥ 14% cells positive) [5, 6]. HER2 is an oncogene associated to BC; in 
recent years this protein has become an important biomarker and target of therapy for almost one third 
of BC patients [7]. The Ki67 protein is a nuclear marker of cell proliferation associated with worse 
outcomes [8]. Biological subtyping by immunohistochemical determination of these four biomarkers 
(i.e. ER, PR, HER2, and Ki67) has statistically significant value in identifying high-risk women with 
hormone receptor-positive BC, independently of standard clinicopathological parameters (including 
age at diagnosis, tumor size, grade, lymphovascular invasion, and axillary lymph node status) [6]. 
Luminal A tumors have lower proliferation and better prognosis than luminal B tumors [9, 10] and are 
more common [6]. 
The gold standard for screening programs of BC is mammography in women above 50 years 
and breast ultrasound in women below 50 years [11]. However, despite substantial increase in the 
number of cases of early-stage BC detected, screening mammography has only marginally reduced the 
rate at which women present with an advanced cancer (8% in the US) [12]. This imbalance suggests 
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that: i) there is substantial overdiagnosis (i.e. the diagnosis of a "cancer" that would otherwise not go 
on to cause symptoms or death), and consequently overtreatment, accounting for nearly a third of all 
newly diagnosed BCs; ii) screening has only a minimal effect on the rate of death from BC [12]. These 
results imply that mammography screening entails a substantial risk of detecting tumors that would not 
have become symptomatic during a woman's lifetime if no screening had taken place, but which are 
nevertheless treated. BC is thus an ideal setting to evaluate alternative screening systems which can 
discriminate between aggressive and non-aggressive cancer, to reduce overtreatment without 
decreasing survival rates. 
There is a growing interest for the application of Surface-enhanced Raman scattering (SERS) in 
diagnostics [13–17]. In this technique, detection is achieved upon adsorption of the analytes of interest 
onto a nanostructured metal surface (i.e. a SERS substrate) having adequate plasmonic properties, 
followed by illumination with a laser light, and analysis of its inelastic scattering using a spectrograph. 
Aqueous colloidal dispersions of Au or Ag nanoparticles are often used as SERS substrates, and they 
are mixed together with the analytes solution. The bands in the SERS spectrum thus obtained are 
related to the molecular vibrations of the chemical species adsorbed on the substrate. Since such a 
spectrum (like Raman or IR spectra) is unique to each molecular structure, it is often considered as a 
kind of “molecular fingerprint”, which is sensitive to changes in the chemical composition of the 
sample, and could thus detect differences between samples belonging to diseased and healthy subjects.  
Recently, several groups reported SERS spectra of blood plasma or serum [16, 18–22], often 
with diagnostic purposes. We also reported that using metal nanoparticles as SERS substrates in the 
absence of aggregating agents, filtration of proteins from serum or plasma is important to rapidly obtain 
intense, repeatable SERS spectra of these biofluids [19]. Furthermore, that study suggested that serum 
should be preferred over plasma, because of the possible spectral interference of anticoagulants, and 
established experimental conditions for obtaining reproducible SERS spectra of serum. 
In the present study, we investigated whether SERS spectroscopy can discriminate serum from 
healthy subjects from that of BC patients, and whether it can further distinguish between BC at 
different stages, i.e. with or without lymph node involvement. However, diagnostically useful 
information, in SERS spectra of a complex chemical mixture such as serum, is often hidden in a wealth 
of spectral data. To extract such meaningful information and use it for diagnostic purposes, we used 
multivariate statistical methods, such as Principal Component Analysis (PCA) and Linear Discriminant 





MATERIALS AND METHODS 
Cohort of samples 
Since SERS spectra depend on metabolites which can be influenced by several factors, our 
strategy was to strictly select homogeneous groups of subjects in order to reduce these factors. We 
aimed to focus on the most widespread conditions, i.e. luminal A histotype BC in menopausal patients 
[4], grouping tumors with different prognosis according to stage: i) early localized small tumors 
(pT1N0M0): better prognosis; ii) advanced tumors with lymph node involvement (pTxN+M0): worse 
prognosis. 
We thus selected 3 groups of participants: 20 healthy women (age range 61.2 ± 8.1); 20 women 
with luminal A BC, stage: pT1N0 (age range 61.6 ± 9.0); and 20 women with luminal A BC, stage: 
pTxN+ (age range 61.8 ± 8.2). We selected patients over 50 years since this is the most frequent age for 
BC diagnosis and a target age for mammary screening [4]. Serum samples were collected at diagnosis, 
so that no therapies could affect the results of our analysis. All participants of the three groups were 
matched for variables related to BC development (Table S1): i) age (individual matching up to 4 age 
difference); ii) menopausal status (all patients are in menopause); iii) Body Mass Index (BMI; 
frequency matching); iv) smoking habits (frequency of smokers or ex-smokers vs. frequency of non-
smokers).  
All serum samples of the 60 subjects were prepared and stored by CRO-Biobank (the biobank of the 
CRO National Cancer Institute, Aviano, Italy), according to Cervo et al. [25]. Briefly, blood samples 
were collected in Serum Z tubes (Monovette®, Sarstedt). After collection, blood tubes were promptly 
placed in ice and centrifuged at 2608 g for 10 minutes at room temperature to separate serum. Aliquots 
of serum were then stored at -80°C.  
 All participants provided written informed consent to participate. The CRO-Biobank project has 
been approved by the CRO Institutional Ethics Committee. 
 
Serum processing 
 Serum aliquots were thawed at room temperature and immediately filtered (Amicon Ultra 3K 
Centrifugal filter devices, cutoff 3 kDa) by centrifugation at 14000 g, 4°C for 75 minutes to enhance 
SERS spectrum, as described in [19]. All samples were stored at −80°C until SERS analysis. 
 
SERS substrates preparation and characterization 
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The SERS spectra were acquired using hydroxylamine-reduced Ag nanoparticles (h-AgNP), 
prepared by the Leopold-Lendl method [26]. Briefly, 0.017 g of AgNO3 were dissolved in 90 mL 
milliQ water, to which a solution consisting of 0.021 g of hydroxylamine hydrochloride and 18 mg of 
NaOH dissolved in 9.5 mL of milliQ water was rapidly added. After few seconds silver colloids were 
obtained which were stable for 1 week (stored in dark at RT).  
All chemicals were purchased from Sigma-Aldrich and used as received. All glassware used for 
h-AgNP preparation was carefully cleaned with strong acids (concentrated HNO3 for Ag colloids) and 
thoroughly rinsed with milliQ water. For all cleaning procedures and preparation of solutions, milliQ 
water was used. To check repeatability between different preparations, h-AgNP colloids were 
characterized by UV-visible absorption spectroscopy after each preparation (Fig. S1 in Supplementary 
Information), using a Lambda 20bio UV-Vis spectrometer (Perkin-Elmer, Monza, Italy). The 
extinction band maxima were at 410 nm, consistent with the values previously reported in literature 
[27], and characteristic of an average nanoparticle diameter of about 23 nm. 
 
SERS instrumentation 
SERS spectra were collected using an InVia Raman microscope (Renishaw plc, Wotton-under-
Edge, UK) equipped with high-power near infrared diode laser (Toptica Photonics AG, Germany) 
emitting at 785 nm and delivering 120 mW of laser power at the sample. For data acquisition, the laser 
was focused on the sample via a 10x microscope objective (N.A. 0.25). A 1800 l/mm grating yielded a 
spectral resolution of 4 cm
-1
. A thermoelectrically cooled charge coupled device (CCD) camera was 
used for detection. The spectrograph was calibrated using the lines of a Ne lamp, and the calibration 
was checked prior to each measurement using the 520 cm
-1
 band of a silicon reference sample. Data 
were acquired using the software WiRE 3.4 (Renishaw). 
 
Sample preparation for SERS measurements 
Filtered serum aliquots were mixed with h-AgNP (prepared as described above and working as 
SERS substrate) in a 1.5 mL polypropylene tube, with a 1:9 biofluid-substrate ratio for a total volume 
of 50 μL (i.e. 4 μL + 45 μL). The mixtures obtained by adding the sample to the h-AgNP were rapidly 
transferred on a vacuum-UV quality CaF2 microscope slide (Crystal GmbH, Berlin, Germany), and 
placed under the Raman microscope for spectral acquisition. CaF2 is devoid of Raman bands in the 
spectral region above 320 cm
-1
, and thus its use avoids any possible spectral interference due to the 
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substrate onto which the liquid sample is deposited. The laser was then focused on the top of the drop, 
and SERS spectra were immediately acquired with an exposure time of 10 s. 
 
Data preprocessing 
All data preprocessing was performed within the R software environment for statistical computing and 
graphics [28]. In particular, data import and export, preprocessing and visualization were performed 
with the hyperSpec package [29] for R. The preprocessing consisted of three steps: i) baseline 
correction ii) smoothing interpolation to project the spectra on an evenly spaced wavenumber axis 
(using the function spc.loess from package hyperSpec), and iii) intensity vector-normalization. For the 
baseline correction, a linear baseline was fit automatically to the whole spectral range and was 
subtracted from each spectrum of the dataset using function modpolyfit from package baseline [30], 
and peak picking was performed using detectPeaks from package MALDIquant [31]. 
 
Multivariate analysis of SERS spectra 
All data analysis was performed within the R software environment for statistical computing and 
graphics [28]. LDA was combined with PCA, into an approach commonly called PCA-LDA (or 
PCLDA), to build a classification model for SERS spectra of serum. PCA was performed to extract the 
most meaningful information out of SERS spectral data, “compacting” the information contained in the 
spectra into a limited set of principal components (PCs) and thus reducing the number of variables to 
be used in LDA. The first 12 PCs, explaining the 99% of spectral variance (see Fig. S2 in 
Supplementary Information), were used in LDA (which was performed using the lda function of 
package MASS [32]). We stress the fact that, in this approach, PCA is only used to reduce the 
dimension of spectral data, and not for an exploratory analysis of the spectral differences between the 
different groups. The PCA-LDA model was then validated using the “Leave-One-Out” (LOO) cross 
validation technique: since there was one spectrum per patient, the validation corresponds to a “leave-
one-patient-out”. It should be noted that for each cross validation step, PCA was carried out each time 
on the training set of data only (all sample but one, as expected in the LOO technique), while the PCs 
for the test sample were calculated, on the basis of the PCA done on the training set, using the 
preProcess function of package caret [33]. In other words, the training and test set were kept 
independent from each other with respect to PCA. The Receiver Operator Curve (ROC) was generated 
by changing the thresholds to determine incorrect and correct classifications for all samples, using the 




RESULTS AND DISCUSSION 
Average SERS spectra of serum samples of healthy subjects (control group) and of patients with a 
diagnosis of a Luminal A BC are shown in Fig. 1, along with their difference. Both spectra present 
features already reported by several groups [16, 18, 20, 21, 35], using various substrates, and in 
particular the bands due to uric acid and hypoxanthine [18, 19, 36].  
The spectra from the two groups of subjects seem very similar, but the difference spectrum 
clearly reveals dissimilarities, where positive and negative peaks correspond, respectively, to 
metabolites present in higher and lower relative amounts in BC patients than in the control group. 
Some positive peaks, and in particular those at 721, 1093, 1324 and 1444 cm
-1
, can be assigned to 
hypoxanthine [18, 19], which thus appears to be present in higher amounts in the serum samples of the 
BC group with respect to the control group. Besides the high number of metabolites present in serum 
(several thousands, reported so far [37]), spectral interpretation is further complicated by surface 
selection rules, which can cause SERS spectra to look very different from the corresponding Raman 
spectra, since the relative intensity of SERS bands depend on the adsorption geometry of the metabolite 
onto the surface of the nanoparticles. We are currently making efforts to identify the metabolites 
corresponding to the other positive and negative peaks. However, the scope of the present study is to 
assess whether the differences between serum SERS spectra of BC patients and of the control group are 
sufficient to differentiate the two groups for diagnostic purposes. 
A separation between the two groups on the basis of SERS spectra was achieved by applying a 
PCA-LDA approach (Fig. S3). A validation of the PCA-LDA model (using LOO cross validation) 
yielded a confusion table (Table S2) from which sensitivity, specificity and accuracy were calculated 
(Table 1). Serum of subjects with BC can be distinguished from those of healthy controls with an 
overall accuracy of 90%, a sensitivity of 92% and a specificity of 85%, which are better than those 
achieved by mammography alone (sensitivity: 67.8%, specificity: 75%) and by mammography 
combined with clinical breast examination (sensitivity: 77.4%, specificity: 72%) [11]. The good 
performance of SERS combined with PCA-LDA as a diagnostic test for BC is also evidenced by the 
ROC curve (Fig. 2), having an AUC of 0.97. 
Besides the ability to simply distinguish BC patients from the controls, we also assessed the 
capability of SERS to classify different types of BC, and in particular those with lymph node 
involvement from those without any involvement. The PCA-LDA applied to the same data but 
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considering three classes (i.e. pT1N0, pTxN+ and controls) instead of two (i.e. BC and controls) 
yielded promising results. Average SERS spectra of serum samples of the pT1N0 and the pTxN+ 
subjects are shown in Fig. 3, along with their difference. Both spectra present features in common with 
the spectra in Fig. 1, but clear differences are present between the two groups. Such dissimilarities, as 
inferred from the difference spectrum (Fig. 3, in grey), are not the same as those found in Fig. 1, 
suggesting that SERS spectra contain information useful to distinguish between the two stages of BC. 
In spite of the still limited biochemical interpretation of SERS bands in serum spectra, these 
preliminary results obtained from a limited number of subjects are encouraging, since PCA-LDA of 
SERS spectra can separate the three groups (Fig. 4), with a promising diagnostic performance. The 
validated PCA-LDA model yielded both sensitivities and specificities above 80%, and an overall 
accuracy of 84% (Table 2).  
Interestingly, the method seems better at detecting early (pT1N0) than locally advanced 
(pTxN+) cancers. Moreover, separation is essentially achieved by the first discriminant function (Fig. 
4), where the pTxN+, unexpectedly, appears to be “in between” the pT1N0 group and the controls. In 
other words, SERS spectra of serum from locally advanced tumors look more similar to spectra from 
the healthy subjects than those of the early cancers. This observation is very intriguing, as it suggests 
that those metabolites detected by SERS, which are discriminating between these two groups of 
patients, might not depend on the tumor burden (i.e. the total amount of tumor cells distributed 
throughout the body) per se but rather on the host. Such a situation is reminiscent of the immune 
response of the host which is more active in early compared to locally advanced tumors [38]. 
Otherwise, our results may suggest that the host is less "aware" of BC tumors which disseminated 
locally than of BC tumor which did not disseminate. 
In conclusion, our data suggest that SERS spectroscopy of serum, in combination with 
multivariate data analysis, represents a promising approach to discriminate healthy subjects from 
subjects having BC with high sensitivity and specificity, and even to distinguish BC at different clinical 
stages, a feature which cannot be achieved with the gold standard method (mammography) currently 
used for screening programs. It should be stressed that, when compared with available diagnostic 
methods, SERS has the advantage of being minimally invasive, easy to use, fast and portable, all 
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Fig. 1. Average normalized SERS spectra of serum samples of the BC group (red, n = 40) and of the 
Control group (black, n = 20), together with their difference spectra (BC – Control, grey). Intensity 








Fig. 2. Receiver Operating Characteristic (ROC) curve of discrimination results for serum SERS 
spectra out of the PCA-LDA-based spectral classification with LOO cross-validation method. The 

















Fig. 3. Average normalized SERS spectra of serum samples of the pT1N0 group (without lymph node 
involvement, red, n = 20) and of the pTxN+ group (with lymph node involvement, blue, n = 20), 
together with their difference spectra (pT1N0 – pTxN+, grey). Intensity standard deviations are 













Fig. 4. Scatter plot of the scores of the first linear discriminant (LD1) against the second linear 
discriminant (LD2), describing the separation between the SERS spectra of the control group (black 
circles), the pTxN+ group (i.e. BC with lymph node involvement; blue triangles) and the pT1N0 group 
(i.e. BC, without lymph node involvement; red crosses) achieved by the PCA-LDA model. The ellipses 
mark the area that contains 95% of the samples (considering data with a bi-variate, normal distribution) 
for each group. Group centroids are indicated as colored filled circles. This plot is shown for 
descriptive (and not predictive) purposes only, since it was obtained from a non-validated PCA-LDA 
model, in which the training set was used as test set. For the predictive performance of the cross-













 Control (%) BC (%) 
Sensitivity 85 92 
Specificity 92 85 
Accuracy 90 
 
Table 1. Diagnostic sensitivity and specificity of the LOO cross validated PCA-LDA classification 
algorithm, applied to SERS spectra of serum, for the classification between serum from Control 







Sensitivity 80 80 90 
Specificity 95 85 95 
Accuracy 84 
 
Table 2. Diagnostic sensitivity and specificity of the LOO cross validated PCA-LDA classification 
algorithm, applied to SERS spectra of serum, for the classification between serum from Control 
patients, BC patients with lymph node involvement (pTxN+) and BC patients without lymph node 
involvement (pT1N0). 
 
 
 
 
